COVID-19 Vaccines: AstraZeneca’s UK Study Not Good Enough For US FDA Authorization, Slaoui Says
Operation Warp Speed chief scientific advisor confirms doubts about the Phase III data from two UK and Brazil studies; says efficacy results in US trials of AstraZeneca and Janssen vaccines expected by mid-January.
You may also be interested in...
AZ and the EU are at loggerheads over supplies of the COVID-19 vaccine. On top of that, its marketing authorization will present dilemmas.
Partners hope non-US regulators will authorize early and then await later readouts to clarify vaccine's profile, but FDA is expected to hold out for US trial data.
Newly public Aligos will team with Merck & Co. on oligonucleotide therapies for NASH. Maze Therapeutics launches ophthalmology and CV-focused spinouts with Alloy and BridgeBio.